MANAGING HIGH-RISK CLL DURING TRANSITION TO A NEW TREATMENT ERA: STEM CELL TRANSPLANTATION OR NOVEL AGENTS?

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E, European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9.

ASSESSMENT OF TP53 FUNCTIONALITY IN CHRONIC LYMPHOCYTIC LEUKEMIA BY DIFFERENT ASSAYS; AN ERIC-WIDE APPROACH

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Br J Haematol. 2014 Nov;167(4):565-9. doi: 10.1111/bjh.13006. No abstract available.

MDM2 PROMOTOR POLYMORPHISM AND DISEASE CHARACTERISTICS IN CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF AN INDIVIDUAL PATIENT DATA-BASED META-ANALYSIS

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nückel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, Greil R, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC).

Haematologica. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170